Celsion announces PFS data from GEN-1 phase I immuno-oncology study in stage III/IV ovarian cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Celsion Corporation announced results from its dose escalating phase IB OVATION I trial evaluating neoadjuvant chemotherapy treatment for six cycles and GEN-1 given weekly for a total of eight doses prior to interval debulking surgery in newly diagnosed patients with stage III/IV ovarian cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more

Login